Medshine Discovery Inc.

China Resources Pharmaceutical Holdings Company Limited

Guizhou Inochini Technology Co., Ltd

Cstone Pharmaceuticals

Chengdu Jinrui Foundation Biotech Co., Ltd.

Cms Research & Development Pte. Ltd.

Cstone Pharmaceuticals Co., Ltd.

Zhaoguo Chen

Shuhui Chen

Fang Liu

Jian Li

Kevin X Chen

Lingyun Wu

Yanxin Yu

Cheng Xie

Lele Zhao

Xinde Chen

Kai Zhou

Guoping Hu

Yuanshan Yao

Boyu Hu

Xiaofei Wang

Peng Zhang

Cailin Wang

Xiawei Wei

Linghui Wu

XiaWei Wei

Jianjun Sun

Fen Jiang

Bin Liu

Huiyu Zhang

Li Zhang

The present invention relates to a group of pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and an application thereof in the preparation of a drug that serves as an HER2 inhibitor. Specifically, the present invention relates to a compound represented by formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof.

Pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and application thereof

Disclosed in the present invention are a crystal form of a [1,2,4]triazolo[1,5-c]pyrimidine compound and a preparation method thereof. Further disclosed is a use of the crystal form in the preparation of a medicament for treating Areceptor related diseases. 

Crystal form a of (5-amino-8-(2-methyl-6-(trifluoromethyl)pyridin-4-yl)-7-phenyl-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)methanol (compound 1)

A cyclopropylamine compound as a lysine-specific demethylase 1 (LSD1) inhibitor. Particularly, the present invention relates to a compound represented by formula (I) and a pharmaceutically acceptable salt thereof. The present invention also provides an application of the same in preparing a drug for treating an LSD1-related disease. 

LSD1 inhibitor and preparation method and application thereof

Disclosed are a series of pyridopyrimidine compounds and a use of same in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors, and specifically disclosed is a use of the compounds as shown in formula (IV), tautomers thereof or pharmaceutically acceptable salts thereof in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors. 

Pyridopyrimidine compounds acting as mTORC 1/2 dual inhibitors

Disclosed are a class of isoquinoline compounds acting as RHO protein kinase inhibitors, and the use thereof in the preparation of a drug for treating diseases associated with RHO protein kinase. Particularly disclosed are compounds as shown in formula (I) and pharmaceutically acceptable salts thereof. 

Sulfonyl-substituted isoquinolines as inhibitors of RHO kinase and hERG potassium channel activity

Provided are a compound represented by formula (I), an isomer or a pharmaceutically acceptable salt thereof, and an application of the same in preparing a drug for treating a disease related to Areceptor. The R, R, R, ring A, ring B, n, and m are as defined in the specification. 

[1,2,4]triazolo[1,5-c]pyrimidine derivative as Areceptor inhibitor

Disclosed is an application of a series of dimethylphosphine oxide compounds in the preparation of an LRRK2 kinase activity inhibitor-related drug, specifically an application of the compound shown in formula (I) or a pharmaceutically acceptable salt thereof in the preparation of an LRRK2 kinase activity inhibitor-related drug.

Dimethylphosphine oxide compound

The present invention discloses a class of isoquinolinesulfonyl derivatives as RHO kinase inhibitors, and pharmaceutical compositions thereof, and relates to pharmaceutically acceptable uses thereof. Specifically, the present invention relates to a compound as represented by formula (I), or a pharmaceutically acceptable salt thereof. 

Isoquinolinesulfonyl derivative as RHO kinase inhibitor

Growing community of inventors

Shanghai, China

Zhaoguo Chen